Literature DB >> 132330

Loading and conventional dose therapy with phenytoin in children: kinetic profile of parent drug and main metabolite in plasma.

J T Wilson, B Höjer, A Rane.   

Abstract

Epileptic children were given phenytoin (DPH) in loading (four doses of 4.4 to 6.3 mg/kg/dose given 8-hourly and then 6 mg/kg/day) or conventional (5 to 9 mg/kg/day) doses. Plasma levels of DPH and its main metabolite (p-OH-DPH) were measured by a mass fragmentographic technique. Plasma DPH levels of more than 10 mug/ml were achieved within 16 to 38 hr in the children given loading doses and within 5 days in the conventionally dosed children. No immediate side effects were noted, but within 8 to 10 days 9 of 13 children developed a generalized skin rash. Plasma p-OH-DPH (free or conjugated) paralleled DPH during the accumulation phase but not during DPH elimination. The ratio of metabolite to DPH in plasma showed both an interindividual variation and an inverse relation to the level of DPH. Identical twins in the study had a similar ratio and plasma level-time course profile. It is concluded that the loading dose regiment achieves an appropriate plasma level of DPH rapidly, that saturation kinetics are operative for p-OH-DPH formation, that the ratio of metabolite to DPH in plasma is an individual characteristic in children, and that further studies on the delayed toxicity are needed before the loading dose regimen can be recommended.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 132330     DOI: 10.1002/cpt197620148

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Serum anticonvulsant concentrations and the risk of drug induced skin eruptions.

Authors:  D Chadwick; M D Shaw; P Foy; M D Rawlins; D M Turnbull
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-06       Impact factor: 10.154

Review 2.  Rational usage of therapeutic drug monitoring in antiepileptic treatment.

Authors:  H Bartels
Journal:  Eur J Pediatr       Date:  1980-05       Impact factor: 3.183

3.  Influence of food on the absorption of phenytoin in man.

Authors:  A Melander; G Brante; O Johansson; T Lindberg; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

4.  Clinical pharmacokinetics in infants and children.

Authors:  A Rane; J T Wilson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

5.  Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.

Authors:  P E Rolan; A J Mercer; R Wootton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

6.  Bioavailability of three phenytoin preparations in healthy subjects and in epileptics.

Authors:  B Rambeck; H E Boenigk; E Stenzel
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

Review 9.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.